BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 30449784)

  • 21. Hepatosplenic T-cell lymphoma presented with massive splenomegaly and pancytopenia - a case report.
    Sukrisman L; Rajabto W; Harahap AS; Fanggidae ESDE; Ham MF; Priantono D
    Klin Onkol; 2023; 36(3):246-250. PubMed ID: 37353354
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term outcome of patients with peripheral T-cell lymphoma treated with first-line intensive chemotherapy followed by autologous stem cell transplantation.
    Prochazka V; Faber E; Raida L; Papajik T; Vondrakova J; Rusinakova Z; Kucerova L; Myslivecek M; Indrak K
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011 Mar; 155(1):63-9. PubMed ID: 21475380
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Autologous stem cell transplantation as frontline strategy for peripheral T-cell lymphoma: A single-centre experience.
    Han X; Zhang W; Zhou D; Ruan J; Duan M; Zhu T; Li J; Cai H; Cao X; Ouyang M
    J Int Med Res; 2017 Feb; 45(1):290-302. PubMed ID: 28222648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation.
    Gkotzamanidou M; Papadimitriou CA
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):248-61. PubMed ID: 24075060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regression of the tumor after withdrawal of cyclosporine in relapsed extranodal natural killer/T cell lymphoma following allogeneic hematopoietic stem cell transplantation.
    Kako S; Izutsu K; Oshima K; Sato H; Kanda Y; Motokura T; Chiba S; Kurokawa M
    Am J Hematol; 2007 Oct; 82(10):937-9. PubMed ID: 17663389
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gemcitabine, dexamethasone and cisplatin (GDP) is an effective and well-tolerated mobilization regimen for relapsed and refractory lymphoma: a single center experience.
    Batgi H; Başcı S; Dal MS; Kızıl Çakar M; Uncu Ulu B; Yiğenoğlu TN; Özcan N; Kılınç A; Merdin A; Yıldız J; Bakırtaş M; Şahin D; Darçın T; İskender D; Baysal NA; Altuntaş F
    Turk J Med Sci; 2021 Apr; 51(2):685-692. PubMed ID: 33237657
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allogeneic bone marrow transplantation for chemotherapy-refractory hepatosplenic gammadelta T-cell lymphoma: case report and review of the literature.
    Domm JA; Thompson M; Kuttesch JF; Acra S; Frangoul H
    J Pediatr Hematol Oncol; 2005 Nov; 27(11):607-10. PubMed ID: 16282893
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prolonged survival of patients with peripheral T-cell lymphoma after first-line intensive sequential chemotherapy with autologous stem cell transplantation.
    Prochazka V; Faber E; Raida L; Vondrakova J; Kucerova L; Jarosova M; Indrak K; Papajik T
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Mar; 153(1):63-6. PubMed ID: 19365529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Umbilical cord blood transplantation induces a durable remission in hepatosplenic gamma-delta T cell lymphoma with associated hemophagocytic lymphohistiocytosis.
    Ayala E; Chalhoub J; Kharfan-Dabaja MA
    Am J Hematol; 2014 Sep; 89(9):934-5. PubMed ID: 24861697
    [No Abstract]   [Full Text] [Related]  

  • 30. Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma-not otherwise specified.
    Qi F; Dong M; He X; Li Y; Wang W; Liu P; Yang J; Gui L; Zhang C; Yang S; Zhou S; Shi Y
    Ann Hematol; 2017 Feb; 96(2):245-251. PubMed ID: 27858107
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center.
    Mikesch JH; Kuhlmann M; Demant A; Krug U; Thoennissen GB; Schmidt E; Kessler T; Schliemann C; Pohlen M; Mohr M; Evers G; Köhler G; Wessling J; Mesters R; Müller-Tidow C; Berdel WE; Thoennissen NH
    Ann Hematol; 2013 Aug; 92(8):1041-8. PubMed ID: 23532626
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Active chemotherapy with gemcitabine, carboplatin and docetaxel for three patients with MVAC-resistant liver metastasis of urothelial carcinoma].
    Inoue T; Ohyama C; Horikawa Y; Togashi H; Matsuura S; Tsuchiya N; Satoh S; Sato K; Habuchi T; Saito S; Hoshi S; Arai Y; Kato T
    Hinyokika Kiyo; 2004 Apr; 50(4):273-7. PubMed ID: 15188623
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study
    Skamene T; Crump M; Savage KJ; Reiman T; Kuruvilla J; Good D; LeBrun D; Meyer RM; Sehn LH; Soulières D; Stakiw J; Laferriere N; Luminari S; Shepherd LE; Djurfeldt M; Zhu L; Chen BE; Hay AE
    Leuk Lymphoma; 2017 Oct; 58(10):2319-2327. PubMed ID: 28504033
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Carboplatin-gemcitabine in the therapy of advanced ovarian cancer: dose reduction consideration.
    Dasanu CA; Herzog TJ; Alexandrescu DT
    J Oncol Pharm Pract; 2010 Mar; 16(1):63-6. PubMed ID: 19525302
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial.
    Tan AR; Wright GS; Thummala AR; Danso MA; Popovic L; Pluard TJ; Han HS; Vojnović Ž; Vasev N; Ma L; Richards DA; Wilks ST; Milenković D; Yang Z; Antal JM; Morris SR; O'Shaughnessy J
    Lancet Oncol; 2019 Nov; 20(11):1587-1601. PubMed ID: 31575503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatosplenic T-cell lymphoma: treatment challenges.
    Bron D; De Leval L; Michiels S; Wittnebel S;
    Curr Opin Oncol; 2021 Sep; 33(5):406-411. PubMed ID: 34409955
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gemcitabine, cisplatin, and dexamethasone (GDP) in combination with methotrexate and pegaspargase is active in newly diagnosed peripheral T cell lymphoma patients: a phase 2, single-center, open-label study in China.
    Zhang Y; Zhang W; Li J; Duan M; Han B; Zhu T; Zhuang J; Cai H; Cao X; Chen M; Zhou D
    Ann Hematol; 2019 Jan; 98(1):143-150. PubMed ID: 30209556
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complete remission in two cases of adult T-cell leukemia/lymphoma treated with hyper-CVAD: a case report and review of the literature.
    Alduaij A; Butera JN; Treaba D; Castillo J
    Clin Lymphoma Myeloma Leuk; 2010 Dec; 10(6):480-3. PubMed ID: 21156467
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A case of refractory pulmonary peripheral T cell lymphoma successfully treated with Cisplatin Plus Gemcitabine Plus Solumedrol].
    Uemura Y; Imai T; Nakajim T; Urata T; Doi H
    Nihon Kokyuki Gakkai Zasshi; 2010 Jan; 48(1):28-32. PubMed ID: 20163018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term survival with allogeneic stem cell transplant and donor lymphocyte infusion following salvage therapy with anti-CD52 monoclonal antibody (Campath) in a patient with alpha/beta hepatosplenic T-cell non-Hodgkin's lymphoma.
    Chanan-Khan A; Islam T; Alam A; Miller KC; Gibbs J; Barcos M; Czuczman MS; Paplham P; Hahn T; McCarthy P
    Leuk Lymphoma; 2004 Aug; 45(8):1673-5. PubMed ID: 15370223
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.